ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial

Inclusion Criteria: * Male patients aged 18 years or above and postmenopausal female patients. * Patients scheduled for elective primary total hip replacement (cemented or non-cemented prosthesis). * Patients' written informed consent for participation after receiving detailed written and oral previous information to any study specific procedures. Exclusion Criteria: * DVT or PE within the previous 6 months prior to study entry. * Myocardial infarction (MI) or cerebrovascular attack (CVA), TIA or ischaemic stroke within the last 6 months prior to study entry. * History of heparin-induced thrombocytopenia, allergy to heparins. * Intracerebral or intraocular bleeding within the last 6 months prior to study entry. * History of gastrointestinal disease with gastrointestinal bleeding within the last 6 months prior to the study. * History or presence of gastrointestinal disease which could result in an impaired absorption of the study drug * Amputation of one leg.Related to current symptoms or findings * Heart insufficiency NYHA III-IV. * Congenital or acquired haemorrhagic diathesis (PT INR/aPTT not within normal limits). * Thrombocytopenia (platelets \< 50.000/µl). * Macroscopic haematuria. * Allergy to contrast media. * Severe hypertension (SBP \> 200mmHg, DBP \> 100 mmHg). * Impaired liver function (transaminases \> 2 x ULN). * Impaired renal function (serum creatinine \> 1.5 x ULN). * Active malignant disease. * Presence of active peptic ulcer or gastrointestinal disease with increased risk of gastrointestinal bleeding. * Body weight \< 45 kg. * Drug- or alcohol abuse. * Related to current treatment * Therapy with oral anticoagulants (e.g. phenprocoumon, warfarin-sodium). * Therapy with acetylic salicylic acid or other thrombocyte aggregation inhibitors (e.g. clopidogrel, dipyridamole and ticlopidine) should be stopped one week before enrolment * Treatment with heparins or Factor Xa Inhibitors other than study medication. * All other drugs influencing coagulation, (exception: NSAIDs with half life \< 17 hrs will be allowed).